National

Germany identifies its first case of new mpox variant

Oct 23, 2024

Berlin [Germany], October 23: Germany has detected its first case of the new mpox variant, the Robert Koch Institute for public health said, adding that it viewed the risk to the wider population as low.
The patient is a 33-year-old man who was isolated after being admitted to hospital for treatment on Oct. 12, the health ministry in the western state of North Rhine-Westphalia said.
The case was detected in Cologne, the ministry said in a statement.
The results of more detailed testing showed on Oct. 18 that the patient had the clade 1b variant, a new form of the virus that is linked to a global health emergency declared by the World Health Organization in August.
The current outbreak originated in the Democratic Republic of Congo and has spread to neighbouring countries.
The patient in Germany is thought to have picked up the virus in an east African country, the state ministry said.
"The RKI currently considers the risk to the health of the general population in Germany to be low," the RKI said, adding it was monitoring the situation closely and would adapt its assessment if necessary.
The RKI noted close physical contact was required for transmission.
The first sign of the virus' spread outside the African continent came on Aug. 15 when global health officials confirmed an infection with a new strain of the mpox virus in Sweden.
Two patients in Norway have been diagnosed with the clade 2 variety of the mpox virus, the Oslo municipality said on Tuesday. Clade 2 is a less severe form of mpox than the clade 1b strain.
Source: Fijian Broadcasting Corporation

More news

CityUHK researchers advance spatial omics to routine clinical use

Hong Kong, September 28: Recently, spatial omics has become a powerful tool, enabling researchers to see not only what molecules are present in a tissue, but also where they are located and how they are organised across cells, tissue structures and local microenvironments. This spatial context has significantly deepened our understanding of cancer, neurobiology and immunology. Yet as the field keeps advancing, an important question remains: How many of these powerful technologies are truly ready for routine clinical use?

Sep 28, 2026